ZYTIGA® Available from Onco360
Onco360 understands the importance of monitoring prostate cancer and we are here to help. We provide ongoing and personalized support to ensure the best clinical expertise, medication adherence, and side effect management.
ZYTIGA® is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with prednisone for the treatment of patients with:
- metastatic castration-resistant prostate cancer (CRPC)
- metastatic high-risk castration-sensitive prostate cancer (CSPC)
ZYTIGA® works by interrupting the androgen-making process at an important step. It inhibits androgen at 3 sources – the testes, adrenal glands, and the tumor itself. Other medications only decrease androgen production in the testes and do not affect the adrenal glands or prostate tumor tissue.
Why is Prednisone included with ZYTIGA®?
To decrease the chance of certain side effects, you must take prednisone with ZYTIGA® exactly as your healthcare provider tells you. Your healthcare provider will check your blood pressure, do blood tests to check your potassium levels, and check for any signs and symptoms of fluid retention every month during treatment with ZYTIGA®. For more information, talk to your doctor.
Take your prednisone exactly how your healthcare provider tells you to. Do not stop taking your prescribed dose of ZYTIGA® or prednisone without talking to your healthcare provider first.
For full prescribing information for ZYTIGA®, visit:
Onco360 is a specialty pharmacy focused on prostate cancer
- #1 in patient2 and provider3 satisfaction*
- Innovative and personalized Prostate MTM program
- Financial assistance sourcing for qualified patients with our OncoAdvocate® Team
- Clinical programs developed by Board-Certified Oncology Pharmacists
- Free delivery to patient’s doorstep
1ZYTIGA® prescribing information: Janssen Biotech, Inc. Accessed 6/22
*Third-party survey data provided by MMIT for Independent Specialty Pharmacies (Oncology). Report dates Q4 20212 and Q3 and Q4 20213.